Improving Psychiatric Drug Benefit Management: III. The VA's Approach to Atypical Antipsychotics

Psychiatric Services

Volumn 55, Issue 1, 2004, Pages 22-23+25

  Sabin, James E ^a,c   Daniels, Norman ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Dept of Ambulatory Care and Prev ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG USE; EDUCATION; EXPERIENCE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HOSPITAL RUNNING COST; HUMAN; MEDICAL DECISION MAKING; MEDICAL ETHICS; MENTAL DISEASE; PATIENT ATTITUDE; PATIENT CARE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHIATRIST; SCHIZOPHRENIA; SHORT SURVEY; TREATMENT OUTCOME; WELLBEING; ARTICLE; COST CONTROL; ECONOMICS; GOVERNMENT; HEALTH INSURANCE; INSURANCE; MANAGEMENT; STANDARD; UNITED STATES;

ANTIPSYCHOTIC AGENTS; COST CONTROL; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MANAGED CARE PROGRAMS; POLICY MAKING; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 2142746956     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.55.1.22     Document Type: Short Survey

References (16)

1. Lohr JB, Braff DL: The value of referring to recently introduced antipsychotics as "second generation." American Journal of Psychiatry 160:1371-1372, 2003
2. Kane J, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry 45:789-796, 1988
3. Rosenheck R, Cramer J, Allan E, et al: Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Archives of General Psychiatry 56:565-572, 1999
4. Sabin JE, Daniels N: Improving psychiatric drug benefit management: I. lessons from Massachusetts. Psychiatric Services 54:949-951, 2003
5. Sabin JE, Daniels N: Improving psychiatric drug benefit management: II. Kaiser Permanente's approach to SSRIs. Psychiatric Services 54:1343-1344,1349, 2003
6. Daniels N, Teagarden RJ, Sabin JE: An ethical template for pharmacy benefits. Health Affairs 22(1):125-137, 2003
7. Daniels N, Sabin JE: Setting Limits Fairly. New York, Oxford University Press, 2002
8. VA Health Care: Implementation of Prescribing Guideline for Atypical Antipsychotic Drugs Generally Sound. US General Accounting Office, April 2002, GAO-02-57. Available at www.gao.gov/new.items/d02579.pdf and www.gao.gov
9. Available at www.hireavet.med.va.gov/govlinks.html
10. Institute of Medicine: Description and Analysis of the VA National Formulary. Washington, DC, National Academy Press, 2000
11. Department of Veterans Affairs Pharmacy Benefits Management, Medical Advisory Panel, and Mental Health Strategic Healthcare Group Guideline for Atypical Antipsychotic Use. Available at www.vapbm.org/guidelines/atypicalantiguidelines.pdf
12. Available at www.catie.unc.edu
13. Rosenheck R, Leslie D: Administrative prescription review procedures and the use of atypical antipsychotic medications in the Department of Veterans Affairs. Mental Health Services Research 5:149-153, 2003
14. Freedman B: Equipoise and the ethics of clinical research. New England Journal of Medicine 317:141-145, 1987
15. Relman AS: Your doctor's drug problem. New York Times, Nov 18, 2003, A-25
16. Available at www.nepec.org